Daratumumab (PBS) provides a CD38-targeting human monoclonal antibody in phosphate-buffered saline (PBS) for multiple myeloma and oncology research and specifically recognizes CD38, a cell-surface glycoprotein highly expressed on many malignant plasma cells. This antibody specifically supports studies of targeted cancer cell recognition, immune-mediated cytotoxicity, and CD38-associated cellular mechanisms.
Key Features and Benefits
- CD38-Targeting Antibody: Provides a human IgG1κ monoclonal antibody that specifically recognizes CD38 on plasma cells and other CD38-expressing cells.
- PBS Formulation: Supplies the antibody in phosphate-buffered saline specifically for research workflows requiring an aqueous buffer formulation.
- CD38 Recognition: Supports investigation of CD38 expression, antibody binding, and antigen-specific cellular interactions.
- Immune-Mediated Cytotoxicity: Supports studies of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- Antibody-Dependent Phagocytosis: Enables investigation of antibody-dependent cellular phagocytosis (ADCP) involving CD38-expressing target cells.
- CD38 Enzymatic Activity: Supports research into CD38-associated NAD metabolism and antibody-mediated modulation of enzymatic functions.
- Immunomodulatory Activity: Enables investigation of CD38-expressing immune cell populations and antibody-associated immune responses.
- Antibody Engineering Platform: Provides a CD38-directed antibody specifically for comparative binding studies and antibody-based research applications.
Applications
- Multiple Myeloma Research: Supports investigation of CD38-targeted antibody mechanisms in multiple myeloma cell models.
- Plasma Cell Malignancy Research: Useful for studying CD38 expression and antibody-mediated cytotoxicity in malignant plasma cells.
- CD38-Positive Cancer Research: Supports investigation of antibody recognition and cellular responses in CD38-expressing cancer models.
- Immuno-Oncology Research: Enables studies of immune effector mechanisms associated with CD38-directed antibody activity.
- ADCC and CDC Assays: Useful for evaluating antibody-dependent cellular cytotoxicity and complement-mediated responses.
- Antibody-Dependent Phagocytosis Studies: Supports investigation of immune cell-mediated recognition and clearance of antibody-coated target cells.
- CD38 Biology Research: Useful for studying CD38 expression, receptor-associated functions, and NAD-related enzymatic activity.
- Antibody Binding Assays: Supports evaluation of CD38 recognition, antigen binding, and antibody-cell interactions.
- Comparative Antibody Research: Useful for comparing CD38-targeting antibodies, immune effector functions, and antibody-mediated cellular responses.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect the PBS formulation from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures specifically for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Daratumumab (PBS) combines CD38-directed antibody recognition with immune-mediated mechanisms involving ADCC, CDC, and ADCP and specifically supports multiple myeloma, plasma cell malignancy, CD38 biology, immuno-oncology, and antibody research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
